Weekly Update: January 9, 2022 to January 27, 2023.
| Cabral P, ResearchSquare, 2022 |
Serial Viral Load Analysis by Ddpcr to Evaluate Fnc Efficacy and Safety in the Treatment of Mild Cases of Covid-19 |
| Cafardi J, JAMA Netw Open, 2022 |
Efficacy and Safety of Pacritinib vs Placebo for Patients With Severe COVID-19: A Phase 2 Randomized Clinical Trial. |
| Corral-Gudino L, Eur J Clin Invest, 2022 |
Effect of intravenous pulses of methylprednisolone 250 mg versus dexamethasone 6 mg in hospitalized adults with severe COVID-19 pneumonia: an open-label randomized trial |
| Denkinger C M, medrxiv, 2022 |
Anti-SARS-CoV-2 antibody containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19 via increased neutralizing antibody activity. A randomized clinical trial |
| Hepprich M, EClinicalMedicine, 2022 |
Canakinumab in patients with COVID-19 and type 2 diabetes - A multicentre, randomised, double-blind, placebo-controlled trial |
| Ilaria Mastrorosa I, SSRN, 2022 |
Sarilumab Plus Standard of Care Versus Standard of Care for the Treatment of Severe COVID-19: A Phase 3, Randomized, Open-Labeled, Multi-Center Study (ESCAPE Study) |
| Jayanthi CR, Adv. Ther, 2022 |
Efficacy and Safety of Inosine Pranobex in COVID-19 Patients: a Multicenter Phase 3 Randomized Double-Blind, Placebo-Controlled Trial |
| Jittamala P, medrxiv, 2022 |
Clinical antiviral efficacy of remdesivir and casirivimab/imdevimab against the SARS-CoV-2 Delta and Omicron variants |
| Ko ER, medrxiv, 2022 |
Abatacept for Treatment of Adults Hospitalized with Moderate or Severe Covid-19 |
| McMahon JH, EClinicalMedicine, 2022 |
Favipiravir in early symptomatic COVID-19, a randomised placebo-controlled trial |
| NCT04448756 |
M5049 Study in Participants With Coronavirus Disease 2019 (COVID-19) Pneumonia |
| NCT04472494 |
Study of Abatacept in the Treatment of Hospitalized COVID-19 Participants With Respiratory Compromise |
| NCT04480424 |
Study to Evaluate the Safety and Efficacy of High Dose Intravenous Immune Globulin (IVIG) Plus Standard Medical Treatment (SMT) Versus SMT Alone in Participants in Intensive Care Unit (ICU) With Coronavirus Disease (COVID-19) |
| O'Halloran J, medrxiv, 2022 |
Infliximab for Treatment of Adults Hospitalized with Moderate or Severe Covid-19 |
| Rein L, Crit Care Med, 2022 |
Randomized Phase 3 Trial of Ruxolitinib for COVID-19-Associated Acute Respiratory Distress Syndrome |
| Salton F, Eur Respir J, 2022 |
Prolonged higher dose methylprednisolone vs. conventional dexamethasone in COVID-19 pneumonia: a randomised controlled trial (MEDEAS). |
| Siami Z, Iran. Red Crescent Med. J, 2022 |
Efficacy and safety of atazanavir/ritonavir versus lopinavir/ritonavir in hospitalized COVID-19 patients: a randomized clinical trial |
| Terada J, Drug Discov Ther, 2022 |
Impact of inhaled ciclesonide on asymptomatic or mild COVID-19: a randomized trial |
| Thorlacius-Ussing L, Sci Rep, 2022 |
A randomized placebo-controlled trial of convalescent plasma for adults hospitalized with COVID-19 pneumonia. |
| Ullah S, Medicina (Kaunas), 2022 |
Assessment of Tocilizumab (Humanized Monoclonal Antibody) for Therapeutic Efficacy and Clinical Safety in Patients with Coronavirus Disease (COVID-19) |
| Villanueva C, medrxiv, 2022 |
Efficacy and safety of convalescent plasma versus standard care in hospitalized patients with COVID-19 from the Peruvian Social Security Health System: open-label, randomized, controlled clinical trial |
| Wu H, PloS one, 2022 |
Low-dose versus high-dose dexamethasone for hospitalized patients with COVID-19 pneumonia: a randomized clinical trial |
| Al Kaabi N, Nat Commun, 2022 |
Safety and immunogenicity of a hybrid-type vaccine booster in BBIBP-CorV recipients: a randomized controlled phase 2 trial |
| Anderson EJ, N Engl J Med, 2022a |
Evaluation of mRNA-1273 Vaccine in Children 6 Months to 5 Years of Age |
| Anez G, medrxiv, 2022 |
Safety, Immunogenicity and Efficacy of NVX-CoV2373 in Adolescents in PREVENT-19: a Randomized, Phase 3 Trial |
| BioNTech SE NCT04816669,2022a |
Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Lyophilized Formulation of BNT162b2 Against COVID-19 in Healthy Adults |
| Charland N, NPJ Vaccines, 2022a |
Safety and immunogenicity of an AS03-adjuvanted plant-based SARS-CoV-2 vaccine in Adults with and without Comorbidities. |
| Cinza-Estevez Z, SSRN, 2022 |
Immunogenicity and Safety Assessment of a SARS-CoV-2 Recombinant Spike RBD Protein Vaccine (Abdala) in Paediatric Ages 3 to 18 Years Old: A Double-Blinded, Multicentre, Randomised, Phase 1/2 Clinical Trial (ISMAELILLO Study) |
| Huang LM, Research Square, 2022 |
Safety and immunogenicity of SARS-CoV-2 vaccine MVC-COV1901 in Taiwanese adolescents: A double-blind, randomized, placebo-controlled phase 2 trial |
| Janssen Vaccines & Prevention ,2023a |
A Study of Ad26.COV2.S Administered as Booster Vaccination in Adults Who Have Previously Received Primary Vaccination With Ad26.COV2.S or BNT162b2 |
| Kulkarni PS, SSRN, 2022 |
Safety and Immunogenicity of SII-NVX-CoV2373 (COVID-19 Vaccine) In Adults in a Phase 2/3, Observer-Blind, Randomised, Controlled Study |
| Kundro MA, Public Health Pract (Oxf), 2022 |
Safety and immunogenicity of heterologous COVID-19 vaccine regimens to deal with product shortage: a randomised clinical trial in an elderly population |
| Leung N H L, medrxiv, 2022 |
Homologous and heterologous boosting with CoronaVac and BNT162b2: a randomized trial (the Cobovax study) |
| Li G, Lancet, 2022 b |
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial. |
| Lien CE, SSRN, 2022 |
A Phase I, Prospective, Randomized, Open-Labeled Study to Evaluate the Safety, Tolerability, and Immunogenicity of Booster Dose with MVC-COV1901 or MVC-COV1901(Beta) SARS-CoV-2 Vaccine in Adults |
| ModernaTX, Inc, 2022a |
Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 COVID-19 Vaccine in Adults Aged 18 Years and Older |
| Mrak D, Nat Commun, 2022 |
Heterologous vector versus homologous mRNA COVID-19 booster vaccination in non-seroconverted immunosuppressed patients: a randomized controlled trial. |
| Niyomnaitham S, Hum Vaccin Immunother, 2022 |
Immunogenicity and reactogenicity against the SARS-CoV-2 variants following heterologous primary series involving CoronaVac, ChAdox1 nCov-19 and BNT162b2 plus BNT162b2 booster vaccination: An open-label randomized study in healthy Thai adul |
| Niyomnaitham S, medrxiv, 2022 |
Immune responses of the third dose of AZD1222 vaccine or BNT162b2 mRNA vaccine after two doses of CoronaVac vaccines against Delta and Omicron variants |
| Niyomnaitham S, vaccines, 2022 |
Evaluation of the Safety and Immunogenicity of Fractional Intradermal COVID-19 Vaccines as a Booster: a Pilot Study |
| Omma A, Hum Vaccin Immunother, 2022 |
Safety and immunogenicity of inactive vaccines as booster doses for COVID-19 in Türkiye: A randomized trial |
| Tang R, SSRN, 2022 |
Safety and Immunogenicity of Aerosolised Ad5-nCoV or Intramuscular Ad5-nCoV or Inactivated COVID-19 Vaccine Coronavac Given as the Second Booster Following Three Doses of CoronaVac: A Multicentre, Open-Label, Phase 4, Randomized Trial |
| Wang L, SSRN, 2022 |
Safety and Cross-Reactive Immune Response Against the Omicron Variant of a Third Dose of CoronaVac, and Immune Persistence of Primary Immunization in Healthy Children and Adolescents: Interim Results from a Double-Blind, Randomised, Placebo |
| Zhang Y, EClinicalMedicine, 2022 |
Immunogenicity, durability, and safety of an mRNA and three platform-based COVID-19 vaccines as a third dose following two doses of CoronaVac in China: a randomised, double-blinded, placebo-controlled, phase 2 trial |
41 early phase vaccine trials where the vaccine dose and schedule have not yet been determined :
| Abarca K, Vaccines, 2022 |
Safety and efficacy of two immunization schedules with an inactivated SARS-CoV-2 vaccine in adults. A randomized non-inferiority clinical trial. |
| Alcamí Pertejo J, SSRN, 2022 |
Immunogenic Dynamics and SARS-CoV-2 Variants Neutralization of the Heterologous ChAdOx1-S/BNT162b2 Vaccination: Secondary Analysis of the CombiVacS Study |
| Angkasekwinai N, Vaccine, 2021 |
Comparison of safety and immunogenicity of CoronaVac and ChAdOx1 against the SARS-CoV-2 circulating variants of concern (Alpha, Delta, Beta) in Thai healthcare workers |
| Baden L, N Engl J Med, 2021 |
Phase 3 Trial of mRNA-1273 during the Delta-Variant Surge |
| Butta N, SSRN, 2022 |
Effect of a COVID-19-Heterologous Vaccination Schedule on Haemostasis: A Subanalysis of the Phase 2, Multicentre, Randomised, Controlled CombiVacS Study |
| Cao Y, Sci China Life Sci, 2022 |
A third high dose of inactivated COVID-19 vaccine induces higher neutralizing antibodies in humans against the Delta and Omicron variants: a Randomized, Double-Blinded Clinical Trial. |
| Capone S, medrxiv, 2022 |
GRAd-COV2 vaccine provides potent and durable immunity in a randomised placebo-controlled phase 2 trial (COVITAR) |
| Chen GL, Lancet microbe, 2022 |
Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial |
| Chen J, 2021 |
[A randomized controlled trial study of immunogenicity and safety of an inactivated SARS-CoV-2 vaccine in different immunization schedules]. |
| Chiuppesi F, Lancet Microbe, 2022 |
Safety and immunogenicity of a synthetic multiantigen modified vaccinia virus Ankara-based COVID-19 vaccine (COH04S1): an open-label and randomised, phase 1 trial. |
| Duc Dang A, Vaccine, 2022 |
Safety and immunogenicity of an egg-based inactivated Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomized, placebo-controlled, phase 1/2 trial in Vietnam. |
| Follmann D, Ann Intern Med, 2022 |
Antinucleocapsid Antibodies After SARS-CoV-2 Infection in the Blinded Phase of the Randomized, Placebo-Controlled mRNA-1273 COVID-19 Vaccine Efficacy Clinical Trial. |
| Garcia-Perez J, eClinicalMedicine, 2022 |
Immunogenic dynamics and SARS-CoV-2 variant neutralisation of the heterologous ChAdOx1-S/BNT162b2 vaccination: Secondary analysis of the randomised CombiVacS study. |
| Han BH, , Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine], 2022 |
Safety of an inactivated 2019-nCoV vaccine (Vero) in adults aged 60 years and older |
| Iwata S, Vaccine, 2022 |
Phase 1/2 Clinical Trial of COVID-19 Vaccine in Japanese Participants: A Report of Interim Findings |
| Jin P, PLoS med, 2022 |
Safety and immunogenicity of heterologous boost immunization with an adenovirus type-5-vectored and protein-subunit-based COVID-19 vaccine (Convidecia/ZF2001): A randomized, observer-blinded, placebo-controlled trial. |
| Leal L, medrxiv, 2022 |
Safety and Immunogenicity of a Recombinant Protein RBD Fusion Heterodimer Vaccine against SARS-CoV-2: preliminary results of a phase 1-2a dose-escalating, randomized, double-blind clinical trial |
| Li J, Adv Therap, 2022 |
Immune Persistence and Safety After SARS-CoV-2 BNT162b1 mRNA Vaccination in Chinese Adults: A Randomized, Placebo-Controlled, Double-Blind Phase 1 Trial. |
| Lin KY, J Formos Med Assoc, 2022 |
Serological response after COVID-19 mRNA-1273 booster dose in immunocompromised patients, Taiwan, July to August 2021. |
| Luo D, Clin Transl Med, 2022 |
A randomized, double-blind, placebo-controlled phase 1 and phase 2 clinical trial to evaluate efficacy and safety of a SARS-CoV-2 vaccine SCoK in adults. |
| Marchevsky NG, eBioMedicine, 2022 |
An exploratory analysis of the response to ChAdOx1 nCoV-19 (AZD1222) vaccine in males and females. |
| Mohraz M, BMJ Open, 2022 |
Safety and immunogenicity of an inactivated virus particle vaccine for SARS-CoV-2, BIV1-CovIran: findings from double-blind, randomised, placebo-controlled, phase I and II clinical trials among healthy adults. |
| NCT04569786 |
Dose Ranging Trial to Assess Safety and Immunogenicity of V590 in Healthy Adults (V590-001) |
| Orozco MN, medrxiv, 2022 |
Phase I study of a SARS-CoV-2 mRNA vaccine PTX-COVID19-B |
| Ozdarendeli A, SSRN, 2022 |
Safety and Immunogenicity of an Inactivated Whole Virion SARS-CoV-2 Vaccine, TURKOVAC, in Healthy Adults: Interim Results from Randomised, Double-Blind, Placebo-Controlled Phase 1 and 2 Trials |
| Pajon R, Nat Med, 2022 |
Initial analysis of viral dynamics and circulating viral variants during the mRNA-1273 Phase 3 COVE trial. |
| Pitisuttithum P, EClinicalMedicine, 2022 |
Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomised, placebo-controlled, phase 1 trial. |
| Pollock KM, eclinicalmedicine, 2022 |
Safety and immunogenicity of a self-amplifying RNA vaccine against COVID-19: COVAC1, a phase I, dose-ranging trial |
| Puthanakit T, vaccines, 2022 |
Immunogenicity of a Fractional Dose of mRNA BNT162b2 COVID-19 Vaccine for Primary Series and Booster Vaccination among Healthy Adolescents. |
| Robbins JA, eBioMedicine, 2022 |
Safety and immunogenicity of intramuscular, single-dose V590 (rVSV-SARS-CoV-2 Vaccine) in healthy adults: Results from a phase 1 randomised, double-blind, placebo-controlled, dose-ranging trial. |
| Saez-Llorens X , SSRN, 2021 |
Safety and Immunogenicity of mRNA-LNP COVID-19 Vaccine CVnCoV in Latin American Adults; A Phase 2 Randomized Study |
| Song JY, EClinicalMedicine, 2022 |
Safety and immunogenicity of a SARS-CoV-2 recombinant protein nanoparticle vaccine (GBP510) adjuvanted with AS03: A randomised, placebo-controlled, observer-blinded phase 1/2 trial. |
| Tanishima M, medRxiv, 2022 |
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, KD-414, in healthy adult and elderly subjects: a randomized, double-blind, placebo-controlled, phase 1/2 clinical study in Japan |
| Thuluva S, EBioMedicine, 2022 |
Evaluation of safety and immunogenicity of receptor-binding domain-based COVID-19 vaccine (Corbevax) to select the optimum formulation in open-label, multicentre, and randomised phase-1/2 and phase-2 clinical trials |
| Thuluva S, medRxiv, 2022 |
Selection of optimum formulation of RBD-based protein sub-unit covid19 vaccine (Corbevax) based on safety and immunogenicity in an open-label, randomized Phase-1 and 2 clinical studies |
| Vanhoutte F, EBioMedicine, 2022 |
Safety and immunogenicity of the measles vector-based SARS-CoV-2 vaccine candidate, V591, in adults: results from a phase 1/2 randomised, double-blind, placebo-controlled, dose-ranging trial |
| Waits A, Int J Infect Dis, 2022 |
Safety and Immunogenicity of MVC-COV1901 Vaccine in Older Adults: phase 2 Randomized Dose-Comparison Trial |
| Wang CY, J Clin Invest, 2022 |
A multitope SARS-COV-2 vaccine provides long-lasting B cell and T cell immunity against Delta and Omicron variants. |
| Wynne C, medRxiv, 2022 |
The preliminary safety and immunogenicity results of a randomized, double-blind, placebo-controlled Phase I trial for a recombinant two-component subunit SARS-CoV-2 vaccine ReCOV |
| Xia S, Front Immunol, 2022 |
Safety and Immunogenicity of an Inactivated COVID-19 Vaccine, WIBP-CorV, in Healthy Children: Interim Analysis of a Randomized, Double-Blind, Controlled, Phase 1/2 Trial. |
| Zhu, Lancet Respir Med., 2022 |
Safety and immunogenicity of a live-attenuated influenza virus vector-based intranasal SARS-CoV-2 vaccine in adults: randomised, double-blind, placebo-controlled, phase 1 and 2 trials |